S 1097 119th Congress
Interagency Patent Coordination and Improvement Act of 2025
A bill to amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Official Title as Introduced Congress.gov
Open official Congress.gov recordSource-linked procedural record
Bill journey
This is a chronology, not a progress score. Politically.com does not classify stages or infer what comes next. Records sharing a date are grouped because not every source field supplies a time.
Congress.gov Recently refreshed
U.S. Senate XML Recently refreshed
-
Introduction Congress.gov
Introduced
Introduced in the Senate.
Open bill recordOfficial action Congress.gov
Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)
Open bill recordOfficial action Congress.gov
Introduced in Senate
Open bill recordText version Congress.gov
Introduced in Senate
A dated text-version record is available.
Open text record -
Official action Congress.gov
Committee on the Judiciary. Ordered to be reported with amendments favorably.
Open bill record -
Official action Congress.gov
Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.
Open bill recordOfficial action Congress.gov
Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
Open bill recordOfficial action Congress.gov
Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.
Open bill recordText version Congress.gov
Reported to Senate
A dated text-version record is available.
Open text record
View the complete bill journey as an accessible table
| Date and time | Record | Official detail | Source |
|---|---|---|---|
| IntroductionIntroduced | Introduced in the Senate. | Congress.gov | |
| Official actionRead twice and referred to the Committee on the Judiciary. (text: CR S1804-1805) | No additional detail supplied.IntroReferral · Senate | Congress.gov | |
| Official actionIntroduced in Senate | No additional detail supplied.IntroReferral · Library of Congress · Code 10000 | Congress.gov | |
| Text versionIntroduced in Senate | A dated text-version record is available. | Congress.gov | |
| Official actionCommittee on the Judiciary. Ordered to be reported with amendments favorably. | No additional detail supplied.Committee · Senate | Congress.gov | |
| Official actionPlaced on Senate Legislative Calendar under General Orders. Calendar No. 41. | No additional detail supplied.Calendars · Senate | Congress.gov | |
| Official actionCommittee on the Judiciary. Reported by Senator Grassley with amendments. Without written report. | No additional detail supplied.Committee · Senate | Congress.gov | |
| Official actionCommittee on the Judiciary. Reported by Senator Grassley with amendments. Without written report. | No additional detail supplied.Committee · Library of Congress · Code 14000 | Congress.gov | |
| Text versionReported to Senate | A dated text-version record is available. | Congress.gov |
House roll calls join only on matching Congress, legislation type, and number. Senate roll calls join only on matching source-supplied document type and number, not question text. Committee and related-measure relationships have no date in their relationship records and therefore are counted above but never placed on the chronology.
Congressional Research Service
CRS summary
Interagency Patent Coordination and Improvement Act of 2025This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.
Official documents
Text versions
- Reported to SenateApr 10, 2025
- Introduced in SenateMar 24, 2025